Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9660056 | 0.82 | PNP (0.31) | — | |
| SCHEMBL8080150 | 0.81 | DPP4 (0.44) | NUDT1 | |
| SCHEMBL3396382 | 0.79 | PNP (0.52) | PDPK1GDA | |
| SCHEMBL2634662 | 0.75 | NUDT1 (0.61) | PDPK1GDANUDT1 | |
| SCHEMBL1251786 | 0.72 | — | — | |
| SCHEMBL16513157 | 0.71 | PDPK1 (0.44) | PDPK1GDA | |
| SCHEMBL5133438 | 0.71 | ADORA2A (0.55) | PDPK1GDANUDT1 | |
| SCHEMBL4907123 | 0.71 | PDPK1 (0.44) | PDPK1GDA | |
| SCHEMBL29062538 | 0.71 | PDPK1 (0.44) | PDPK1GDA | |
| SCHEMBL1705024 | 0.71 | PDPK1 (0.44) | PDPK1GDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7560550-B2 | Method for the production of OH protected[4-(2.6-diamino-9H-purine-9-yl)-1.3-dioxolane-2-yl]methanol derivatives | RFS PHARMA, LLC (US) | 2009-07-14 | — | — | US | disclosed |
| EP-1648894-B1 | METHOD FOR THE PRODUCTION OF OH PROTECTED [4-(2.6-DIAMINO-9H-PURINE-9-YL)- 1.3-DIOXOLANE-2-YL]METHANOL DERIVATIVES | WACKER CHEMIE AG (DE) | 2007-09-12 | — | — | EP | disclosed |
| US-20060211855-A1 | Method for the production of oh protected{4-(2.6-diamino-9h-purine-9-yl)-1.3-dioxolane-2-yl] methanol derivatives | WACKER CHEMIE AG (DE) | 2006-09-21 | — | — | US | disclosed |
| EP-1648894-A1 | METHOD FOR THE PRODUCTION OF OH PROTECTED [4-(2.6-DIAMINO-9H-PURINE-9-YL)- 1.3-DIOXOLANE-2-YL]METHANOL DERIVATIVES | Wacker Chemie AG (DE) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005012302-A1 | METHOD FOR THE PRODUCTION OF OH PROTECTED [4-(2.6-DIAMINO-9H-PURINE-9-YL)- 1.3-DIOXOLANE-2-YL]METHANOL DERIVATIVES | WACKER CHEMIE AG (DE) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211855-A1 | Method for the production of oh protected{4-(2.6-diamino-9h-purine-9-yl)-1.3-dioxolane-2-yl] methanol derivatives | FUT6, FUT5, ST6GAL1 | PDPK1 2047/4885GDA 131/4885NUDT1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.